SPU Archives - Page 3 of 3 - Blue Horseshoe Stocks

Blue Horseshoe Stocks: SPU, MAXD Recap & More

Friday’s Hot Picks

We had a couple plays that we tagged in Friday morning’s premarket report that went on to provide traders with a good chance at some intraday gains.

SkyPeople Fruit Juice, Inc. SPU – We put SPU on watch after noticing the strong session it recorded on Thursday, and the momentum carryover was pretty impressive. From an early low of 4.35, took of and hit a high of 7.90. That worked out to an intraday jump of 82% which came on over 17X the 3-month average volume.

______

MaxSound Corp. MAXD – Also performing well was MAXD, which we tracked over an impressive range from the .002’s to the .008’s back in early April. We circled back around to it at an opportune time on Friday, as the stock launched from .0043 on up to .0064, logging a 49% pop on the day.

Marinus Pharmaceuticals, Inc. MRNS – Update

We want to give our readers a quick reminder on MRNS this morning, a stock we recently tagged with the intent of seeing it try to fill the massive gap on the chart.

After seeing 1.35 following that alert, the stock began to do just that as it hit a high of 2.23 on Friday. That’s a 65% run-up so far, and we’re going to be very interested to see how the activity unfolds as we kick off this new trading week.

Avinger, Inc. AVGR

Speaking of stocks with enormous gaps to fill on their charts, we also want to begin monitoring AVGR, which, as you can see on the snapshot below, is in a position similar to that of MRNS when we began tracking it a couple weeks back.

The stock is searching for a bottom after taking a massive gut punch in the form of a three-dollar gap-down. While it appears it may yet have some bottoming out to do, it’s egregiously oversold at the moment, and we’ll want to be there when its own recovery begins as the resulting rebound could carry some substantial gain opportunities along with it.

Extended Watchlist:
BILB, SGBY, TGD, CIDM, NXTD, OPTT,

Blue Horseshoe Stocks: Updates, Fresh Plays & More

Kraig Biocraft Laboratories, Inc. KBLB

We alerted KBLB in Wednesday morning’s premarket report, and on that day, we would observe a PPS low of .0261. Yesterday, the stock hit a high of .0395, for a respectable two-session upswing of 51%

Following that solid run-up, we saw the stock close at .0375, maintaining a vast majority of its advance. We’ll continue to keep a steady eye on KBLB, and look for it to maintain support above the .03-mark in order to keep us interested.

Potential Bottom-Plays

Rennova Health, Inc. RNVA – We have an interesting story unfolding with RNVA, and a potential rebound opportunity as well. After briefly cracking its 50DMA on Wednesday, the stock took a major gut punch yesterday as it gapped down immensely.

It seems a bit of an overreaction after reading the PR that apparently catalyzed the selloff. The company announced yesterday that it had priced a public offering with the intent of raising upwards of $8.6M in capital, expected to close by Tuesday. They set the purchase price at .45, which is why a massive slide to less than .30 seemed disproportionate.

We’ll be interested to see the activity in this now majorly-oversold stock in sessions to come.

__________

Ampio Pharmaceuticals, Inc. AMPE – Speaking of stocks that have recently gapped down hard and found new lows, we have AMPE hitting our bottom-play radar.

Similar to the aforementioned play, the selloff occurred as a result of what some might construe as over-reactive. The company released data from a clinical study at the end of last month on its osteoarthritis injection treatment that was poorly-received. However, while the primary endpoints of the double-blind study were not met, the treatment was markedly effective in improving the patients with the most extreme cases of the condition.

So the study was not a total loss, and the company made clear its intent to submit an FDA application for the treatment for those severely afflicted patients that were helped, and for whom no other non-surgical alternative exists.

That’s why we’ll be keeping an eye on AMPE to continue to regain some of its lost ground, as it has done over the past few sessions.

Extended Watchlist:
MAXD, MFST, PPHM, FES, SPU, KURA, COSI(Bottom watch)

Blue Horseshoe Stocks: IMSC Update & More

Implant Sciences Corp. IMSC

We caught IMSC earlier this week on Tuesday, as it popped up on a routine news scan that morning; the company had announced a potentially lucrative contract with the TSA and the stock was gapping up pretty big.

It took a couple of sessions for the stock to come down and find support, and yesterday following an update on the TSA contract in which we learned that the initial order for over 1100 explosive detectors to be deployed in airports across the country was received, the stock began to run. >> Read PR

From an early low of 1.26 IMSC made a nice 22% intraday move, topping out at 1.54. We want to continue to pay attention to this play as the week comes to a close, in the wake of this morning’s Q1 2015 earnings release, which contains some favorable figures:

Implant Sciences Reports First Quarter Fiscal 2015 Financial Results (Fri 7:00AM EST)

Off of Today’s News Scan

We’ll group our Extended Watchlist items together with links to the important PR’s each of the companies has out this morning.

Armco Metals Holdings, Inc. AMCO released earnings which beat expectations: ARMCO METALS HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report (Fri 8:32AM EST)

Geron Corp. GERN licensed its cancer treatment to a unit of Johnson & Johnson for up to $935 million: Geron could get $935M in blood disorder drug deal (Thu, Nov 13)

SkyPeople Fruit Juice, Inc. SPU announced vastly increased Q3 revs:SkyPeople Q3 Revenue Up 79% to $34.8 Million, Net Income Increases 45% to $4.7 Million (Fri 6:00AM EST)

Blonder Tongue Laboratories, Inc. BDR also released earnings today: BLONDER TONGUE LABORATORIES INC Files SEC form 10-Q, Quarterly Report (Fri 8:31AM EST)

Immunocellular Therapeutics, Inc. IMUC announced continued favorable results from trials of their dendritic cell-based immunotherapeutic vaccine: ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data at the Society for Neuro-Oncology Annual Meeting 2014 (Fri 6:00AM EST)